Paroxysmal nocturnal haemoglobinuria (PNH) manifesting on CT as a pathologic segment of small bowel
Radiology Case Reports, 2017 Paroxysmal nocturnal haemoglobinuria, a rare, acquired, life-threatening disease of the blood, is characterised by a triad of haemolysis previously believed to occur mainly at night, bone marrow dysfunction, and thrombophilia.
David Zekria MPhys, DPhil, MBBS, +1 more
doaj +2 more sources
How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future [PDF]
British Journal of Haematology, 2022 Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by complement‐mediated intravascular haemolysis, severe thrombophilia and bone marrow failure.
Antonio Maria Risitano
exaly +3 more sources
Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
Hematology, Transfusion and Cell Therapy, 2021 Paroxysmal nocturnal hemoglobinuria is a chronic, multi-systemic, progressive and life-threatening disease characterized by intravascular hemolysis, thrombotic events, serious infections and bone marrow failure.
Rodolfo D. Cançado +8 more
doaj +2 more sources
eJHaem, 2022 A 47‐year‐old male with paroxysmal nocturnal haemoglobinuria (PNH) controlled with routine ravulizumab administration suffered a massive haemolytic crisis due to choledocholithiasis.
Mitsuru Moriyama +6 more
doaj +2 more sources
Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]
Thrombosis Journal, 2018 Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Francesco Dragoni +4 more
doaj +2 more sources
Thrombotic Events in Patients With Paroxysmal Nocturnal Haemoglobinuria Using Eculizumab: A Post‐Marketing Surveillance Sub‐Analysis [PDF]
eJHaemBackground Thrombotic events (TEs) account for approximately 40%–67% of deaths in untreated paroxysmal nocturnal haemoglobinuria (PNH). C5 inhibitor treatment (e.g., eculizumab and ravulizumab) greatly reduces the incidence of TEs in patients with PNH ...
Takayuki Ikezoe +4 more
doaj +2 more sources
Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor‐Naive Patients With Paroxysmal Nocturnal Haemoglobinuria [PDF]
eJHaemBackground Paroxysmal nocturnal haemoglobinuria (PNH) is characterised by haemolytic anaemia, bone marrow failure and thrombosis. The single‐arm phase 3 APPOINT‐PNH trial (NCT04820530) investigating iptacopan monotherapy in complement inhibitor‐naive ...
Matthew Holt +8 more
doaj +2 more sources
Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria: Real World Data From Denmark and Finland [PDF]
eJHaemIntroduction Ravulizumab replaced eculizumab as the preferred complement inhibitor for Paroxysmal Nocturnal Haemoglobinuria (PNH) in Denmark and Finland after 2020. Data on real‐world disease activity after switching are limited.
Anders Rønneholt‐Frederiksen +8 more
doaj +2 more sources
Acute Necrotizing Pancreatitis Complicated with Paroxysmal Nocturnal Haemoglobinuria: A Case Report [PDF]
Clinical and Experimental GastroenterologyMengbo Xiao,1 Ying Di,1 Yu An,1 Yunfeng Cui2 1Tianjin Medical University, Tianjin, People’s Republic of China; 2Department of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Tianjin Nankai Hospital, Nankai Clinical School of Medicine ...
Xiao M, Di Y, An Y, Cui Y
doaj +2 more sources
Thromboembolic events and haematological diseases: a case of stroke as clinical onset of a paroxysmal nocturnal haemoglobinuria [PDF]
Thrombosis Journal, 2004 Some haematological diseases are associated to an increased risk of thromboembolic events. We report a case of paroxysmal nocturnal haemoglobinuria (PNH) in which a cerebrovascular event represented the first clinical manifestation of disease.
Viggiano Vito +8 more
doaj +2 more sources